Neuroendocrine Tumor

News alerts, weekly reports and conference planners

EML4-ALK fusion	Neuroendocrine Tumor	EML4-ALK fusion	Neuroendocrine Tumor	alectinib Sensitive: C4 – Case Studies Ann Transl Med - 4 days (New C4) alectinib Sensitive : C4 Ann Transl Med - 4d	alectinib Sensitive: C4 – Case Studies Ann Transl Med - 4 days alectinib Sensitive : C4 Ann Transl Med - 4 days - (New C4)
No biomarker	Neuroendocrine Tumor	No biomarker	Neuroendocrine Tumor	surufatinib Sensitive: A1 - Approval surufatinib Sensitive : A1	surufatinib Sensitive: A1 - Approval surufatinib Sensitive : A1
No biomarker	Neuroendocrine Tumor	No biomarker	Neuroendocrine Tumor	sunitinib Sensitive: A1 - Approval sunitinib Sensitive : A1	sunitinib Sensitive: A1 - Approval sunitinib Sensitive : A1
No biomarker	Neuroendocrine Tumor	No biomarker	Neuroendocrine Tumor	everolimus Sensitive: A1 - Approval everolimus Sensitive : A1	everolimus Sensitive: A1 - Approval everolimus Sensitive : A1
No biomarker	Neuroendocrine Tumor	No biomarker	Neuroendocrine Tumor	lanreotide prolonged-release subcutaneous Sensitive: A1 - Approval lanreotide prolonged-release subcutaneous Sensitive : A1	lanreotide prolonged-release subcutaneous Sensitive: A1 - Approval lanreotide prolonged-release subcutaneous Sensitive : A1
No biomarker	Neuroendocrine Tumor	No biomarker	Neuroendocrine Tumor	sunitinib Sensitive: A1 - Approval sunitinib Sensitive : A1	sunitinib Sensitive: A1 - Approval sunitinib Sensitive : A1
VHL mutation	Neuroendocrine Tumor	VHL mutation	Neuroendocrine Tumor	belzutifan Sensitive: A1 - Approval belzutifan Sensitive : C1	belzutifan Sensitive: A1 - Approval belzutifan Sensitive : C1
No biomarker	Neuroendocrine Tumor	No biomarker	Neuroendocrine Tumor	EP Sensitive: A2 - Guideline EP Sensitive : A2	EP Sensitive: A2 - Guideline EP Sensitive : A2
No biomarker	Neuroendocrine Tumor	No biomarker	Neuroendocrine Tumor	octreotide Sensitive: A2 - Guideline octreotide Sensitive : A2	octreotide Sensitive: A2 - Guideline octreotide Sensitive : A2
No biomarker	Neuroendocrine Tumor	No biomarker	Neuroendocrine Tumor	temozolomide Sensitive: A2 - Guideline temozolomide Sensitive : A2	temozolomide Sensitive: A2 - Guideline temozolomide Sensitive : A2
SSTR positive	Neuroendocrine Tumor	SSTR positive	Neuroendocrine Tumor	lanreotide prolonged-release subcutaneous Sensitive: A2 - Guideline lanreotide prolonged-release subcutaneous Sensitive : A2	lanreotide prolonged-release subcutaneous Sensitive: A2 - Guideline lanreotide prolonged-release subcutaneous Sensitive : A2
SSTR positive	Neuroendocrine Tumor	SSTR positive	Neuroendocrine Tumor	octreotide Sensitive: A2 - Guideline octreotide Sensitive : A2	octreotide Sensitive: A2 - Guideline octreotide Sensitive : A2
No biomarker	Neuroendocrine Tumor	No biomarker	Neuroendocrine Tumor	FOLFOX Sensitive: A2 - Guideline FOLFOX Sensitive : A2	FOLFOX Sensitive: A2 - Guideline FOLFOX Sensitive : A2
No biomarker	Neuroendocrine Tumor	No biomarker	Neuroendocrine Tumor	carboplatin + etoposide IV Sensitive: A2 - Guideline carboplatin + etoposide IV Sensitive : A2	carboplatin + etoposide IV Sensitive: A2 - Guideline carboplatin + etoposide IV Sensitive : A2
No biomarker	Neuroendocrine Tumor	No biomarker	Neuroendocrine Tumor	temozolomide + capecitabine Sensitive: A2 - Guideline temozolomide + capecitabine Sensitive : A2	temozolomide + capecitabine Sensitive: A2 - Guideline temozolomide + capecitabine Sensitive : A2
BRAF V600E	Neuroendocrine Tumor	BRAF V600E	Neuroendocrine Tumor	trametinib + dabrafenib Sensitive: A2 - Guideline trametinib + dabrafenib Sensitive : C1	trametinib + dabrafenib Sensitive: A2 - Guideline trametinib + dabrafenib Sensitive : C1
MSI-H/dMMR	Neuroendocrine Tumor	MSI-H/dMMR	Neuroendocrine Tumor	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : C1	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : C1
No biomarker	Neuroendocrine Tumor	No biomarker	Neuroendocrine Tumor	oxaliplatin Sensitive: A2 - Guideline oxaliplatin Sensitive : A2	oxaliplatin Sensitive: A2 - Guideline oxaliplatin Sensitive : A2
No biomarker	Neuroendocrine Tumor	No biomarker	Neuroendocrine Tumor	dacarbazine Sensitive: A2 - Guideline dacarbazine Sensitive : A2	dacarbazine Sensitive: A2 - Guideline dacarbazine Sensitive : A2
RET fusion	Neuroendocrine Tumor	RET fusion	Neuroendocrine Tumor	selpercatinib Sensitive: A2 - Guideline selpercatinib Sensitive : C1	selpercatinib Sensitive: A2 - Guideline selpercatinib Sensitive : C1
No biomarker	Neuroendocrine Tumor	No biomarker	Neuroendocrine Tumor	cisplatin + etoposide IV Sensitive: A2 - Guideline cisplatin + etoposide IV Sensitive : A2	cisplatin + etoposide IV Sensitive: A2 - Guideline cisplatin + etoposide IV Sensitive : A2
No biomarker	Neuroendocrine Tumor	No biomarker	Neuroendocrine Tumor	5-fluorouracil Sensitive: A2 - Guideline 5-fluorouracil Sensitive : A2	5-fluorouracil Sensitive: A2 - Guideline 5-fluorouracil Sensitive : A2
No biomarker	Neuroendocrine Tumor	No biomarker	Neuroendocrine Tumor	capecitabine Sensitive: A2 - Guideline capecitabine Sensitive : A2	capecitabine Sensitive: A2 - Guideline capecitabine Sensitive : A2
No biomarker	Neuroendocrine Tumor	No biomarker	Neuroendocrine Tumor	nivolumab + ipilimumab Sensitive: A2 - Guideline nivolumab + ipilimumab Sensitive : A2	nivolumab + ipilimumab Sensitive: A2 - Guideline nivolumab + ipilimumab Sensitive : A2
No biomarker	Neuroendocrine Tumor	No biomarker	Neuroendocrine Tumor	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
No biomarker	Neuroendocrine Tumor	No biomarker	Neuroendocrine Tumor	FOLFIRINOX Sensitive: A2 - Guideline FOLFIRINOX Sensitive : A2	FOLFIRINOX Sensitive: A2 - Guideline FOLFIRINOX Sensitive : A2
No biomarker	Neuroendocrine Tumor	No biomarker	Neuroendocrine Tumor	carboplatin + irinotecan Sensitive: A2 - Guideline carboplatin + irinotecan Sensitive : A2	carboplatin + irinotecan Sensitive: A2 - Guideline carboplatin + irinotecan Sensitive : A2
No biomarker	Neuroendocrine Tumor	No biomarker	Neuroendocrine Tumor	cisplatin + irinotecan Sensitive: A2 - Guideline cisplatin + irinotecan Sensitive : A2	cisplatin + irinotecan Sensitive: A2 - Guideline cisplatin + irinotecan Sensitive : A2
No biomarker	Neuroendocrine Tumor	No biomarker	Neuroendocrine Tumor	FOLFIRI Sensitive: A2 - Guideline FOLFIRI Sensitive : A2	FOLFIRI Sensitive: A2 - Guideline FOLFIRI Sensitive : A2
No biomarker	Neuroendocrine Tumor	No biomarker	Neuroendocrine Tumor	CAPOX Sensitive: A2 - Guideline CAPOX Sensitive : A2	CAPOX Sensitive: A2 - Guideline CAPOX Sensitive : A2
No biomarker	Neuroendocrine Tumor	No biomarker	Neuroendocrine Tumor	5-fluorouracil + streptozocin Sensitive: A2 - Guideline 5-fluorouracil + streptozocin Sensitive : A2	5-fluorouracil + streptozocin Sensitive: A2 - Guideline 5-fluorouracil + streptozocin Sensitive : A2
No biomarker	Neuroendocrine Tumor	No biomarker	Neuroendocrine Tumor	doxorubicin hydrochloride + streptozocin Sensitive: A2 - Guideline doxorubicin hydrochloride + streptozocin Sensitive : A2	doxorubicin hydrochloride + streptozocin Sensitive: A2 - Guideline doxorubicin hydrochloride + streptozocin Sensitive : A2
No biomarker	Neuroendocrine Tumor	No biomarker	Neuroendocrine Tumor	streptozocin Sensitive: A2 - Guideline streptozocin Sensitive : A2	streptozocin Sensitive: A2 - Guideline streptozocin Sensitive : A2

Neuroendocrine Tumor

Associations(88)

Associations
(88)